Open AccessLong‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
Author(s) -
Maravalle Denise,
Filosa Alessandra,
Bigazzi Catia,
Collina Guido,
Galieni Piero
Publication year - 2022
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.388
Subject(s) - decitabine , medicine , venetoclax , leukemia cutis , cytarabine , oncology , regimen , myeloid , cd33 , myeloid leukemia , leukemia , gastroenterology , biochemistry , gene expression , chemistry , chronic lymphocytic leukemia , dna methylation , gene , genetics , stem cell , biology , cd34
In February 2020, a 74‐year‐old female was diagnosed with myelomonocytic acute myeloid leukaemia with FLT3 mutation and blasts positive for CD33, BCL‐2 and CD68/PGM1. Not responding to a standard Cytarabine–containing regimen plus Midostaurin, the patient achieved a complete remission (CR) of the disease in the bone marrow following a reinduction therapy with high‐dose Cytarabine but simultaneously relapsed developing leukaemia cutis with disseminated lesions in 80% of the body surface area. After receiving 10 cycles of Decitabine plus Venetoclax the patient achieved and maintains a continuous CR.